Matthias Buente
Matthias has more than 25 years of consulting as well as line management experience. He spent most of his professional life in Management consulting at two of the world's leading strategy consulting firms, but also gained some line management experience as General Manager in the biotech industry at two leading global biotech companies in Middle East & Africa.
His key areas of expertise are product and portfolio strategies for pharma companies, disruptive growth strategies especially in emerging markets, but also functional excellence from R&D, safety, pricing and market access to the impact of digital on the commercial strategy and the operating model of his clients.
Matthias holds a Diploma in Physics and a PhD in Astrophysics from ETH Zurich.
Future of health 2 – The rise of healthcare platforms
Study, September 30, 2020
Global Pharma Study 2024 – a new age of performance programs
Study, October 22, 2024
The era of free drug-pricing in the US has come to an end
Article, September 17, 2024
Unlocking value in the CDMOs market
Article, July 3, 2024
US pharmaceutical pricing at a crossroads
Article, February 5, 2024
Cell and gene therapies: Strategies for commercial success
Article, November 14, 2023
Robotics in surgery
STUDY, June 13, 2023
Beyond the numbers: Key characteristics of successful pharma companies
Study, May 24, 2023
Will environmental sustainability hold sway over the pharmaceuticals industry?
Article, November 29, 2022
Mastering supply chain crises in the pharmaceutical industry
Article, July 11, 2022
Future of health 3 - How the phygital model is going to transform healthcare
Study, September 24, 2021
Cell and gene therapies: Pharma's next big wave
Study, May 5, 2021
The Future of Medical Affairs: Creating value as never before
White paper, December 11, 2019